B Group Inc. Makes New $5.55 Million Investment in Cellectis S.A. (NASDAQ:CLLS)

B Group Inc. purchased a new position in shares of Cellectis S.A. (NASDAQ:CLLS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 3,081,501 shares of the biotechnology company's stock, valued at approximately $5,547,000. Cellectis accounts for about 3.4% of B Group Inc.'s investment portfolio, making the stock its 7th biggest holding. B Group Inc. owned 5.54% of Cellectis at the end of the most recent quarter.

Separately, Wells Fargo & Company MN raised its position in Cellectis by 103.4% in the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock valued at $44,000 after buying an additional 12,500 shares during the last quarter. Institutional investors and hedge funds own 63.90% of the company's stock.

Cellectis Stock Up 1.3 %

Shares of NASDAQ:CLLS traded up $0.02 during midday trading on Friday, hitting $1.53. The stock had a trading volume of 81,346 shares, compared to its average volume of 145,698. The business's 50-day simple moving average is $1.33 and its 200-day simple moving average is $1.62. Cellectis S.A. has a 12 month low of $1.10 and a 12 month high of $3.38. The company has a market cap of $85.04 million, a P/E ratio of -1.18 and a beta of 3.22. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48.

Cellectis (NASDAQ:CLLS - Get Free Report) last issued its earnings results on Thursday, March 13th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.06 by ($0.22). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The firm had revenue of $33.22 million during the quarter, compared to the consensus estimate of $5.90 million. On average, sell-side analysts forecast that Cellectis S.A. will post -0.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, StockNews.com raised Cellectis from a "hold" rating to a "buy" rating in a research report on Friday.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.